HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
- Wednesday, March 15, 2023, 7:07
- Finance
- Add a comment
Company Anticipates No Impact on U.S. and European Royalty Revenues from DARZALEX FASPRO® and SC through at least 2030 Reiterates 2023 Revenue Guidance of $815 million to $845 million and Royalty Revenue of $445 million to $455 million SAN DIEGO, March 15, 2023 /PRNewswire/ — Halozyme…
About the Author
adminasapcorp has written 41562 stories on this site.